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induction of SCD in rats resulted only in a transient 
loss of NogoA+, but not Olig2+ cells during the demyeli-
nation phase. This phase was followed by complete oligo-
dendroglial repopulation and remyelination, even after four 
episodes of demyelination. Our data indicate efficient oli-
godendroglial repopulation in subpial cortical lesions in rats 
after repeated SCD that was similar to early, but not chronic 
MS cases. Accordingly, four cycles of experimental de- and 
remyelination were not sufficient to induce sustained remy-
elination failure as found in chronic cortical MS lesions. This 
suggests that alternative mechanisms contribute to oligoden-
drocyte depletion in chronic cortical demyelination in MS.
Keywords Multiple sclerosis · Cortical demyelination · 
Oligodendrocytes · Oligodendrocyte precursors · Targeted 
cortical eAe
Introduction
Multiple sclerosis (MS) is characterized by multifocal 
inflammatory demyelinating lesions in white and gray 
Abstract Cerebral cortex shows a high endogenous pro-
pensity for remyelination. Yet, widespread subpial cortical 
demyelination (SCD) is a common feature in progressive 
multiple sclerosis (MS) and can already be found in early 
MS. In the present study, we compared oligodendroglial loss 
in SCD in early and chronic MS. Furthermore, we addressed 
in an experimental model whether repeated episodes of 
inflammatory SCD could alter oligodendroglial repopulation 
and subsequently lead to persistently demyelinated cortical 
lesions. NogoA+ mature oligodendrocytes and Olig2+ oligo-
dendrocyte precursor cells were examined in SCD in patients 
with early and chronic MS, normal-appearing MS cortex, 
and control cortex as well as in the rat model of repeated tar-
geted cortical experimental autoimmune encephalomyelitis 
(eAe). NogoA+ and Olig2+ cells were significantly reduced 
in SCD in patients with chronic, but not early MS. repeated 
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matter of the central nervous system (CNS) [31]. Neocorti-
cal demyelination in particular is a frequent phenomenon 
found in 90 % of patients with chronic MS [30, 50], but can 
already be present in patients with early MS [34]. Despite 
early description of neocortical lesions in MS [6], these 
lesions have mostly been overlooked until recently since 
they are difficult to detect with traditional staining tech-
niques [41] or conventional magnetic resonance imaging 
(MrI) [17, 27]. The use of new MrI sequences has shown 
that cortical lesions in MS are more common than previ-
ously thought [8, 17, 26] and are supposed to contribute 
to cognitive impairment [7, 44] and epilepsy [9] in MS. 
Therefore, cortical involvement may represent an important 
pathophysiological substrate for disease manifestation, pro-
gression and therapy in MS [12, 18, 30].
On average, between 10 and 25 % of cortical gray mat-
ter (gM) is demyelinated in patients with chronic MS, but 
individual patients may even reach values of over 70 % [5, 
19, 30]. During the progressive stage of the disease, the 
extent of gM demyelination can even exceed that of white 
matter (WM) demyelination [19, 30]. Histopathologically, 
three main types of cortical lesions have been described 
according to their topographic distribution within the cere-
bral cortex: leukocortical (type I) lesions extending through 
WM and gM, purely intracortical (type II) lesions and 
subpial (type III) lesions [41]. Subpial cortical demyelina-
tion (SCD), the most frequent lesion type in chronic MS, 
accounts for the majority of demyelinated cortex and seems 
to occur independent of WM demyelination [3, 30]. Com-
pared to WM lesions, cortical demyelination presents with 
less lymphocyte infiltration and reduced microglia activa-
tion [4, 41, 48]. However, the extent of meningeal inflam-
mation was shown to correlate with the extent of cortical 
demyelination and rate of progression in patients with sec-
ondary progressive MS [24, 35, 36]. Similarly, meningeal 
and intracortical infiltrates were topographically associated 
with cortical lesions in early-stage MS, which supports 
the concept that inflammatory processes underlie cortical 
demyelination [34].
Despite the observation that gM lesions have a higher 
remyelination propensity than WM lesions [2, 12], chronic 
cortical demyelinated lesions accumulate over time and are 
most widespread in progressive MS [30]. It has been postu-
lated that the depletion of oligodendrocyte precursor cells 
(OPCs) [10] and oligodendroglial differentiation block [15, 
29] could account for remyelination failure in WM lesions. 
Previous experimental studies furthermore suggested that 
repeated rounds of de- and remyelination lead to less effi-
cient remyelination in WM [25].
In the present study, we analyzed cortical oligodendro-
cytes (Ols) and OPCs in early- and late-stage MS. Our 
findings reveal that both mature Ols and their precursors 
are significantly reduced in demyelinated cerebral cortex in 
late-stage, but not in early MS. To address whether repeated 
cycles of cortical de- and remyelination could account for 
the depletion of Ols and lack of remyelination, we used 
a rat model of targeted cortical experimental autoimmune 
encephalomyelitis (eAe) which recreates key histopatho-
logical features of cortical MS lesions [38]. Here, we 
induced up to four consecutive cortical eAe lesions within 
the same cortical area and investigated the impact on repop-
ulation of Ols and remyelination. We found that the dif-
ferentiation of OPCs into mature Ols was not sustainably 
impaired even after repeated cortical de- and remyelination. 
Our study thus suggests that cortical remyelination failure 
in MS is not necessarily due to repeated waves of de- and 
remyelination. Further studies are required to unravel the 
mechanisms underlying cortical remyelination failure in 
progressive MS.
Materials and methods
Clinical data and human tissue
Brain samples were fixed in 4 % formaldehyde and par-
affin embedded. Blocks consisted of five autopsy cases 
with chronic MS [mean age 54.2 (range 41–66) years; 
mean disease duration 16.8 (range 10–25) years] as 
well as four biopsy cases with early MS [mean age 36.8 
(range 26–45) years; mean disease duration 3.3 (range 
2–6) months]. Tissue blocks from age- and sex-matched 
control autopsy cases without neurological disease 
[n = 10; 5 males, 5 females; mean age 50.3 (range 35–
75) years] served as controls. For the detection of SCD, 
paraffin sections were immunostained for myelin basic 
protein (MBP). Clinical data are summarized in Table 1 
(autopsy cases) and Table 2 (biopsy cases). All MS 
autopsy cases showed a progressive disease course with 
disease durations of at least 10 years, whereas biopsy 
cases suffered from early MS. Based on the number of 
relapses, biopsy cases were either classified as clinically 
isolated syndrome (CIS) (n = 3) or relapsing–remitting 
MS (n = 1) as indicated in Table 2. Biopsies were per-
formed for diagnostic purposes to exclude neoplastic or 
Table 1  Clinical findings of MS autopsy cases
MS autopsy 
case
Age Sex Disease  
duration (years)
Disease course
1 47 F 25 Secondary progressive
2 66 M 12 Primary progressive
3 41 M 10 Progressive
4 60 F 25 Secondary progressive
5 57 M 12 Secondary progressive
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infectious diseases. The study was approved by the ethics 
committee of the University Medical Center göttingen 
(WF-004/11).
Histology and immunohistochemistry on human tissue
Bielschowsky silver staining and immunohistochemistry 
were carried out according to standard procedures. The 
following primary antibodies were used: rabbit anti-MBP 
(1:1,000, Dako, Denmark), mouse anti-MBP peptide70–89 
(SMI94; 1:3,000, Covance, Princeton, New Jersey, USA), 
mouse anti-KiM1P (1:5,000) [43], rabbit anti-Olig2 (1:100, 
IBl, Spring lake Park, Minnesota, USA), mouse anti-
NogoA (1:10,000, mAb 11C7, a generous gift from M.e. 
Schwab, Brain research Institute, eTH and University of 
Zurich, Switzerland) and mouse anti-Ki67 (1:50, clone 
Mib-1, Dako, Denmark). To identify Olig2+ or NogoA+ 
cells in control non-MS, normal-appearing MS and demy-
elinated MS neocortex, we performed double-immuno-
labeling combining either rabbit anti-Olig2 with mouse 
anti-MBP70–89 (SMI94) or mouse anti-NogoA with rabbit 
anti-MBP.
Double-labeling immunohistochemistry was performed 
combining DAB (first primary antibody) and Fast Blue 
(second primary antibody with APAAP; Dako). For fluores-
cence double-labeling, Cy3- or Cy2-conjugated goat anti-
mouse Igg and goat anti-rabbit Igg (both from Jackson 
Immunoresearch europe ltd.) were used.
Morphometry and statistics on human tissue
The density of KiM1P+, NogoA+ and Olig2 strongly 
positive (Olig2+) cells was determined as ≥20,000 μm2. 
KiM1P+ mononuclear cells of both macrophage and 
microglia phenotype were counted in SCD in layers I/II 
and in layer III and given as cells/mm2. The mean num-
ber of Olig2+ and NogoA+ cells was quantified in layers 
I/II and in layer III in control non-MS neocortex, normal-
appearing MS neocortex (NAgM) as well as chronic and 
early SCD.
The density of axons (layer III) was assessed on Biels-
chowsky silver-stained sections (1000×) in control non-
MS neocortex, MS NAgM as well as chronic SCD within 
at least four visual fields using a 10 × 10 counting grid. 
Axonal density was given in percent of control non-MS 
neocortex as a reference (set to 100 %).
Animals and groups
A total number of 101 adult female lewis rats (195 g ± 15, 
Harlan, Horst, Netherlands) were included in this study. 
The animals were kept in groups (maximum 8 animals per 
cage) on a 12:12 h light/dark cycle with food and water Ta
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provided ad libitum. All experiments were approved by the 
Bezirksregierung Braunschweig, germany.
Sensitization procedure
recombinant rat myelin oligodendrocyte glycoprotein 
(rMOg) was produced as described previously [1]. For 
subclinical immunization, anaesthetized rats (n = 68) were 
injected subcutaneously (s.c.) with rMOg (50 μg) emulsi-
fied in incomplete Freund’s adjuvant (IFA; Sigma-Aldrich 
Chemie gmbH, Steinheim, germany) as described previ-
ously [38]. For control experiments, rats (n = 27) were 
injected s.c. with PBS emulsified in IFA. A subset of ani-
mals (n = 6) received no injection (naive controls).
Intracerebral stereotactic injection
Stereotactic injections were performed according to a 
modified protocol as described previously [38]. Briefly, 
anaesthetized IFA- or rMOg-sensitized rats received a first 
stereotactic injection into the cortex (1 mm caudal to the 
bregma, 2 mm lateral to the sagittal suture, 1.7 mm depth) 
19–21 days after immunization. 1 μl of a cytokine mixture 
[250 ng of recombinant rat tumor necrosis factor-α (TNF-α; 
r&D Systems, Abingdon, UK; 150 U of recombinant rat 
interferon-γ (IFN-γ; PeproTech, london, UK)] dissolved 
in PBS was injected together with a trace of Monastral blue 
(Fluka, germany). Stereotactic cytokine injection at the 
same anatomical location was repeated up to four times at 
intervals of 21 days.
5-Bromo-2-deoxyuridine (BrdU) injection
BrdU labeling was performed in a subset of IFA- or 
rMOg-sensitized animals (n = 6 per group). Animals were 
injected twice daily intraperitoneally with 1.5 ml 0.9 % 
NaCl solution containing 100 mg/kg bodyweight BrdU 
(Sigma) for 5 days starting on day 2 after cytokine injec-
tion. At 21 days after cytokine injection, the animals were 
killed for histology.
Histopathology and immunohistochemistry of rat tissue
Animals were anaesthetized by injecting an overdose of 
14 % chloral hydrate (Merck). After transcardial perfu-
sion with 4 % paraformaldehyde, brains were dissected and 
paraffin embedded. Serial brain sections (2 μm) were col-
lected from the injection site. Immunohistochemistry was 
performed as described above. Additional antibodies used 
were: mouse anti-proteolipid protein (PlP, clone Plpc1, 
1:2,500, Biozol), mouse anti-BrdU (1:400 in 10 % FCS, 
Chemicon) and mouse anti-eD1 (activated macrophages/
microglia, 1:1,000, Serotec).
Morphometric analysis of focal cortical eAe lesions
Images were captured using light and fluorescence micro-
scopes equipped with a digital camera (Color View II and 
DP71, Olympus, germany). NogoA+ and Olig2+ cell pop-
ulations were determined on NogoA/MBP and Olig2/MBP 
double-stained sections. The density of both cell popula-
tions was assessed in cortical layers I and II (400×) using 
a 10 × 10 counting grid and expressed as cells per mm2. 
The size of the demyelinated area was quantified on MBP-
immunostained sections using Analysis® software (Analy-
sis, Soft Imaging System, germany).
Axonal density was quantified on Bielschowsky silver-
impregnated sections as described above and given in 
percent of untreated controls. The fraction of myelinated 
axons was determined in cortical layer III within four vis-
ual fields (1000×) using a counting grid (10 × 10 squares). 
The numbers of MBP+ myelin sheaths and Bielschowsky-
impregnated axons intersecting with the crosses of the 
counting grid were determined. The ratio of MBP+ fib-
ers and Bielschowsky-impregnated axons was calculated 
(expressed in % of axons).
To quantify proliferated OPCs, Olig2 and BrdU double-
positive cells were assessed on fluorescence images (200×) 
of cortical layers I/II (3 optical fields per animal). The 
quantification applied a custom-made script based on Cog-
nition Network language (Definiens Cognition Network 
Technology; Definiens Developer XD software) and resem-
bled previously described scripts [28, 37]. Briefly, cells 
showing (a) an overlapping signal in the BrdU and Olig2 
channel and (b) a signal for DAPI staining (nuclei) were 
counted and expressed as cells per mm2.
Statistical analysis
Statistical analysis was performed using SPSS (Version 12, 
SPSS Inc., Chicago, Il, USA) or graphPad Prism (graph-
Pad Prism Software, Ink, San Diego, California, USA). Nor-
mality of distribution was tested by Kolmogorov–Smirnov 
tests. Statistical calculations included one-way analysis of 
variance (ANOVA) if three or more groups were compared, 
followed by post hoc least significance difference (lSD) test 
as indicated in the figure legends. For comparisons between 
two groups, unpaired t tests were performed.
The subanalysis within MS autopsy cases used paired t 
tests to compare the cell and axonal densities in demyeli-
nated MS neocortical layers versus adjacent MS NAgM. 
To test for altered cell densities in SCD between chronic 
(autopsies) and early (biopsies) MS cases, Mann–Whit-
ney tests were performed. A probability value of less than 
0.05 was considered significant. All data are expressed as 
mean ± standard error of the mean (SeM) and shown in 
graphs as mean + SeM.
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Results
Subpial cortical demyelination in early and chronic MS
SCD is prominent in most patients with chronic MS [30], 
but can already be present in early MS [34]. We detected 
SCD affecting layers I–III in all selected MS biopsy (n = 4; 
Fig. 1a) and autopsy (n = 5, Fig. 1b) cases. In addition, all 
MS autopsy cases also showed adjacent normal-appearing 
myelinated cortical layers I–III (Fig. 1b). In contrast, most 
tissue blocks from the investigated MS biopsy cases exhib-
ited only demyelinated layers I–III, thereby restricting the 
analysis of biopsies to demyelinated areas only. All control 
cases displayed intact neocortical myelin.
Subpial cortical lesions were classified as inac-
tive demyelinated lesions in all MS autopsy (n = 5) and 
biopsy (n = 4) cases based on the absence of myelin-laden 
phagocytes. Since the short disease duration in biopsy 
cases ranged from 2 to 6 months, we investigated whether 
these early (biopsy) cases displayed increased mac-
rophage and microglia infiltration in SCD compared to late 
(autopsy) cases. The quantitative analysis in demyelinated 
cortical layers I/II showed significantly higher densities of 
KiM1P+ cells in early biopsy cases (194.8 ± 36.6 cells/
mm2) (Fig. 2a) compared to late autopsy cases with MS 
(50.4 ± 16.9 cells/mm2; p < 0.05) (Fig. 2b, c). Similarly, 
the densities of KiM1P+ cells in demyelinated cortical layer 
III were also significantly increased in early MS (biopsy) 
(174.6 ± 16.4 cells/mm2) (Fig. 2d) compared to late MS 
(autopsy) (35.6 ± 6.7 cells/mm2; p < 0.05) (Fig 2e, f) 
cases. Thus, the more pronounced microglia and mac-
rophage activation supported the assumption that SCD 
noted in biopsies evolved more recently than SCD observed 
in autopsy brain samples.
Marked reduction of oligodendrocytes in chronic, but not 
early subpial MS lesions
To investigate whether oligodendroglial densities in SCD 
are affected by disease duration, we quantified the density 
of NogoA+ Ols in SCD in patients with a short (early MS) 
or a long (chronic MS) disease duration.
We first assessed the density of NogoA+ Ols in the 
superficial layers I/II. Autopsy cases displayed similar 
numbers of NogoA+ cells in the control cortex (32.4 ± 4.2 
cells/mm2, Fig. 3a) compared to normal-appearing MS cor-
tex (NAgM) (33.4 ± 4 cells/mm2, Fig. 3b, e). SCD areas 
of progressive MS patients showed a significant decrease 
of NogoA+ Ols in the superficial layers (3 + 0.8 cells/
mm2, Fig. 3c) compared to adjacent normal-appearing 
layers I/II (p < 0.01, Fig. 3b, e). In contrast, NogoA+ cell 
numbers in layers I/II were unaltered in SCD of patients 
with early MS (38.8 + 16.6 cells/mm2, Fig. 3d) as com-
pared to control and MS NAgM (Fig. 3e). The analysis 
of demyelinated layers I/II showed a trend toward higher 
numbers of NogoA+ cells in patients with early versus late 
MS (p = 0.06).
We further quantified NogoA+ Ols in layer III in MS 
and control autopsy cases. MS NAgM displayed similar 
densities of NogoA+ cells (33.1 ± 4.8 cells/mm2) as con-
trol cortex (24.2 ± 5 cells/mm2) in layer III (Fig. 3f, g). In 
progressive MS patients, NogoA+ Ols were significantly 
reduced in demyelinated layer III (3.6 ± 1.1 cells/mm2, 
Fig. 3h) compared to adjacent normal-appearing layer III 
(p < 0.01, Fig. 3g, j). In contrast, patients with early MS 
showed similar oligodendroglial numbers in demyelinated 
layer III (23.7 ± 7.8 cells/mm2, Fig. 3i) as control and MS 
NAgM (Fig. 3j). Significantly more NogoA+ Ols were 
detected in demyelinated layer III in patients with early dis-
ease than in patients with chronic MS (p < 0.05).
Fig. 1  Subpial cortical demyelination in early and chronic MS 
cases. Immunohistochemistry for MBP (blue) reveals subpial cortical 
demyelination (SCD) in early (biopsy) (a) and chronic (autopsy) (b) 
cases with MS. a exemplary biopsy tissue from one of the patients 
with early MS shows confluent SCD affecting cortical layers I–III. b 
exemplary section from one of the autopsy cases with long-standing 
MS displays the transition zone of normal-appearing myelinated cor-
tex (on the left) and SCD (on the right). Arrows indicate the border of 
the cortical demyelination. Scale bars 1 mm in a and b
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reduced density of oligodendrocyte precursor cells (OPCs) 
in chronic, but not early MS lesions
To address whether the density of OPCs in subpial cortical 
lesions is affected by disease duration, we quantified OPCs 
in SCD in early versus late MS. Olig2 is strongly expressed 
in OPCs and weakly in mature Ols in the adult human 
CNS [29]. Thus, we only counted the number of Olig2 
strong+ cells (referred to as Olig2+ cells).
The densities of Olig2+ cells in the superficial layers I/II 
were similar in control (22.7 ± 3.5 cells/mm2, Fig. 4a) and 
MS NAgM (21.1 ± 4.8 cells/mm2, Fig. 4b, e). Within pro-
gressive MS cases, Olig2+ cell numbers were decreased in 
demyelinated layers I/II (4.3 ± 0.7 cells/mm2, Fig. 4c) com-
pared to adjacent normal-appearing layers I/II (p = 0.05, 
Fig. 4b, e). In contrast, OPC density was not altered in 
early SCD of patients with early MS (29.3 ± 14.4 cells/
mm2, Fig. 4d) and showed a trend toward higher densities 
compared to chronic SCD (p = 0.06, Fig. 4e). However, we 
could not detect Olig2+ cells that co-expressed the prolif-
eration marker Ki67 within SCD in these biopsies, indicat-
ing that OPCs might have proliferated already before the 
bioptic surgery took place (data not shown).
We also assessed Olig2+ progenitors in the outer pyram-
idal layer III. The control (17.3 ± 1.5 cells/mm2, Fig. 4f) 
and MS NAgM (20.2 ± 2.9 cells/mm2, Fig. 4g) displayed 
similar densities of Olig2+ OPCs in layer III. In chronic 
MS cases, there was a significant reduction of Olig2+ cells 
in demyelinated layer III (7.1 ± 1.8 cells/mm2, Fig. 4h) 
compared to adjacent normal-appearing layer III (p < 0.05, 
Fig. 4g, j). In contrast, early SCD showed no reduction of 
Olig2+ cells in layer III (35.9 ± 9.4 cells/mm2, Fig. 4i) 
compared to control (Fig. 4f) and MS NAgM (Fig. 4g, j). 
The density of Olig2+ cells in layer III was significantly 
reduced in chronic compared to early SCD (p < 0.05, 
Fig. 4j). Furthermore, the quantification of axonal densities 
in layer III of chronic SCD did not reveal any significant 
reduction compared to controls or NAgM (Suppl. Fig. 1). 
Taken together, these results suggest that Ols and their pre-
cursors are not reduced in SCD in early MS, but show a 
marked decline in progressive disease.
efficient oligodendroglial regeneration after recurrent 
demyelinating episodes in rats with targeted cortical eAe 
lesions
We aimed to examine experimentally whether consecu-
tive episodes of SCD might lead to loss of oligodendro-
glial cells and exhaustion of remyelination. Therefore, we 
induced repeated SCD within the same anatomical area in 
an established animal model of MS. In this model, exten-
sive cortical remyelination has already been demonstrated 
after a single demyelinating episode [38]. In the present 
study, we induced up to four consecutive targeted cortical 
eAe lesions by repeated stereotactic intracortical cytokine 
injection (for experimental setup see Fig. 5). As described 
previously [38], rMOg-immunized rats showed extensive 
SCD on day 3 after a single intracerebral cytokine injection 
Fig. 2  Marked microglia/macrophage activation in early, but not 
chronic subpial MS lesions. a–f Immunohistochemistry for KiM1P+ 
macrophages and microglia in SCD of chronic (autopsy) and early 
(biopsy) cases with MS. representative images show KiM1P+ cells 
within early (a) and chronic (b) SCD of cortical layers I/II as well as 
the quantification thereof (c). representative images show KiM1P+ 
cells in early (d) and chronic (e) SCD within cortical layer III as 
well as the quantification thereof (f). Black arrowheads point toward 
exemplary KiM1P+ cells. Insets in a, b, d and e show KiM1P+ cells 
in greater detail. Scale bars 25 μm in a, b, d, e; error bars indicate 
SeM. *p < 0.05
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(Fig. 6a–c). SCD extended along the pial surface of the 
ipsilateral hemisphere, reminiscent of subpial type III cor-
tical MS lesions. In contrast, the contralateral cortex was 
devoid of demyelination (Fig. 6d–f).
To assess the impact of repetitive SCD on oligodendro-
glial regeneration, we then performed repeated intracorti-
cal cytokine injections every 3 weeks up to four times into 
the same anatomical area (see experimental setup Fig. 5). 
We first assessed the densities of NogoA+ Ols at the dif-
ferent experimental time points and conditions. Three 
days after the last cytokine injection, NogoA+ Ols were 
significantly reduced in rMOg-immunized rats with one 
(4.9 ± 1.5 cells/mm2; p < 0.01), two (9.2 ± 2.8 cells/mm2, 
p < 0.05) and four (6.8 ± 2.8 cells/mm2; p < 0.01) demyeli-
nating episodes compared to untreated controls (19.3 ± 2.1 
cells/mm2) (Fig. 7a, b). After this initial drop of Ols, a 
substantial repopulation of NogoA+ cells was observed in 
rMOg-immunized animals 3 weeks after single, twofold 
and fourfold lesion induction (Fig. 7b). Three weeks after 
the last injection, animals with one (16.3 ± 3.6 cells/mm2) 
and two (20.8 ± 3.5 cells/mm2) demyelinating episodes 
showed similar densities of NogoA+ cells as untreated con-
trols. Three weeks following the fourth lesion, there was 
a trend toward reduced NogoA+ cells compared to age-
matched controls (11.1 ± 2.7 cells/mm2 versus 19.3 ± 2.6 
cells/mm2; p = 0.052). To investigate whether this trend 
reflected a final stage or rather a delay in oligodendro-
glial recruitment, NogoA+ cells were quantified later at 
35 days after the fourth injection in rMOg-immunized rats 
(Fig. 7b). At this later time point, NogoA+ cell density was 
similar to control levels (p = 0.36) (Fig. 7b).
We then set out to examine cortical Olig2+ OPCs 
(Fig. 8a, b). Three days after the first lesion induction, the 
density of Olig2+ cells was not reduced in demyelinated 
Fig. 3  reduction of oligodendrocytes in cortical layers I/II and layer 
III in chronic, but not early MS lesions. a–j Immunohistochemistry 
for MBP (blue) and NogoA+ Ols (brown) within layers I/II (a–d) or 
layer III (f–i), respectively, and the corresponding quantitative evalu-
ation (e, j). representative images of control cortex (a, f), normal-
appearing cortex (NAgM) of chronic MS (b, g) as well as chronic (c, 
h) or early (d, i) SCD. Similar numbers of NogoA+ cells are noted 
in cortical layers I/II (a, b, d, e) and layer III (f, g, i, j) in the con-
trol cortex (a, f), NAgM (b, g) and SCD from patients with early MS 
(d, i). In patients with chronic MS, NogoA+ cells are significantly 
reduced in chronic SCD (c, h) in cortical layers I/II (c) and III (h) 
each compared to the corresponding NAgM area. The densities of 
NogoA+ Ols in layer III are significantly decreased in chronic SCD 
compared to early SCD (j), whereas there is a trend for the group 
comparison within layers I/II (e) (p = 0.06). NogoA+ cells are indi-
cated by black arrowheads and shown in detail in insets. Scale bars 
25 μm in a–d and f–i; error bars indicate SeM. *p < 0.05, **p < 0.01
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cortex (45.8 ± 2.9 cells/mm2) and similar to non-lesioned 
controls (45.7 ± 2.5 cells/mm2, Fig. 8b). Three weeks after 
the first lesion induction, however, the density of Olig2+ 
cells was significantly increased in rMOg-immunized rats 
(60.1 ± 6.2 cells/mm2) compared to untreated controls 
(p < 0.01), to rMOg-immunized rats on day 3 (p < 0.01) 
and to cytokine-injected controls (40.8 ± 1.0 cells/mm2; 
p < 0.01).
To examine OPC proliferation after lesion induction, 
Olig2 and BrdU double-positive cells were quantified 
in the cortex in animals pretreated with the proliferation 
marker BrdU. Three weeks after single lesion induction, 
the density of Olig2/BrdU double-positive cells was sig-
nificantly increased in previously demyelinated cortex as 
compared to the non-demyelinated control group (Suppl. 
Fig. 2).
Following the second and fourth demyelinating epi-
sode, the Olig2+ cell density was already increased on day 
3 after the last injection in rMOg-immunized rats (2nd 
injection 54.1 ± 3.1 cells/mm2, p < 0.05; 4th injection 
59.9 ± 5.2 cells/mm2) compared to repeatedly injected con-
trols (Fig. 8a, b). Furthermore, 3 weeks after the second and 
fourth injection, the numbers of Olig2+ cells were unaltered 
in rMOg-immunized rats compared to controls. These find-
ings therefore indicate that OPC numbers were not reduced 
within SCD even after repeated lesion induction.
efficient remyelination after transient acute demyelination 
in rats with repeated focal lesioning
To compare cortical de- and remyelination after 
repeated lesioning, animals were evaluated on day 3 for 
Fig. 4  reduced oligodendrocyte precursors in chronic, but not early 
MS lesions. a–j Immunohistochemistry for OPCs with strong Olig2 
expression (Olig2+ cells) (brown) and MBP-positive myelin (blue) 
within layers I/II (a–d) or layer III (f–i), respectively, and the cor-
responding quantitative evaluation (e, j). representative images are 
shown of control cortex (a, f), normal-appearing cortex (NAgM) of 
chronic MS (b, g) as well as chronic (c, h) and early (d, i) SCD. Sim-
ilar numbers of Olig2+ cells are noted in myelinated cortical layers 
I/II (e) or layer III (j) in control cortex, MS NAgM and SCD from 
patients with early MS. In layers I/II, there is a trend for decreased 
Olig2+ OPCs in chronic SCD (autopsy) (c) compared to either 
adjacent NAgM (p = 0.05) or demyelinated early SCD (biopsy) 
(p = 0.06) (e). In layer III Olig2+ cells are significantly reduced in 
chronic SCD (h, j) compared to NAgM and early SCD (p < 0.05 for 
both comparisons). Olig2+ cells are indicated by black arrowheads 
and shown in detail in insets. Scale bars 25 μm in a–d and f–i; error 
bars indicate SeM. *p < 0.05
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demyelination and on day 21 for remyelination after final 
lesion induction following one, two and four stereotactic 
cytokine injections.
First, we examined whether repeated cytokine injection 
was associated with the activation of microglia and mac-
rophages in rMOg-immunized animals (Fig. 9). Three 
days after single, twofold and fourfold lesion induction, 
the density of activated eD1+ microglia and macrophages 
was substantially increased in layer III of the ipsilateral 
cortex (1st injection 537.1 ± 56.6 cells/mm2, 2nd injection 
485.3 ± 52.8 cells/mm2, 4th injection 360 ± 66.3 cells/m2) 
in rMOg-immunized rats compared to cytokine-injected 
control animals (1st injection 56.0 ± 10.7 cells/mm2, 4th 
injection 72 ± 4.6 cells/m2, p < 0.001). The infiltration with 
eD1+ cells was transient in rMOg-immunized animals and 
dropped again to control levels on day 21 after last lesion 
induction (Fig. 9).
Fig. 5  experimental setup for cortical targeted eAe induction in 
rats. Animals were immunized with rMOg emulsified in incom-
plete Freund’s adjuvant (IFA). Controls (not depicted in the graph) 
were immunized with IFA only. 20 days later, cytokines were stereo-
tactically injected into the cortex either once (top row), twice (mid-
dle row) or four times (bottom row) with 3 weeks time interval(s) 
between each injection
Fig. 6  Focal subpial cortical demyelination in the ipsilateral, but 
not contralateral cortex after intracerebral cytokine injection in 
rMOg-immunized rats. a–f representative photographs of MBP-
immunostained cortex of rMOg-primed rats on day 3 post-lesion 
induction (a–c). extensive ipsilateral demyelination is present 3 days 
after intracortical cytokine injection in rMOg-immunized rats. Tar-
geted lesion is indicated by arrow marking the injected blue dye. d–f 
In contrast, the contralateral non-injected hemisphere displays intact 
myelin. Scale bars a and f 500 μm, b–e 100 μm
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SCD appeared widespread on MBP-immunostained sec-
tions following 3 days after single, two- or fourfold cytokine 
injection in rMOg-immunized rats (Fig. 10a). In contrast, 
IFA-immunized controls did not show any signs of demyeli-
nation on day 3 after the final cytokine injection (Fig. 10a). In 
rMOg-immunized animals on day 3 following the last injec-
tion, there was a similar degree of cortical demyelination 
in rats after one (1.5 ± 2.7 mm2), two (1.7 ± 0.2 mm2) or 
four (1.8 ± 0.3 mm2) demyelinating episodes (Fig. 10b). All 
rMOg-immunized animals showed a significant reduction of 
the demyelinated area at 3 weeks after final lesion induction 
compared to the corresponding group on day 3 (1st injec-
tion 0.3 ± 0.1 mm2, p < 0.001, 2nd injection 0.5 ± 0.2 mm2, 
p < 0.01, 4th injection 0.4 ± 0.1 mm2, p < 0.001). The size 
of the demyelinated cortical area after 3 weeks was similar in 
all rMOg-immunized animals—irrespective of the number 
of cytokine injections (Fig. 10b). These findings indicate that 
cortical remyelination is not impaired even after repeated 
inflammatory demyelination within the same area.
To assess the proportion of remyelinated axons, we 
quantified axons and myelin fibers after repeated lesioning. 
Axonal morphology appeared normal, adjacent to the injec-
tion site (Suppl. Fig. 3), and axonal densities in layer III 
resembled untreated control levels after one, two and four 
stereotactic cytokine injections (Suppl. Fig. 3). To exam-
ine whether the density of remyelinated fibers remained 
stable following recurrent cortical demyelination, we cal-
culated the ratio between the density of myelinated fib-
ers and axons in cortical layer III at different time points 
(Fig. 10c). In controls the fraction of myelinated cortical 
Fig. 7  efficient repopulation 
with cortical NogoA+ oligoden-
drocytes after repeated cycles of 
cortical demyelination in rats. 
a representative photographs 
of NogoA-immunostained sec-
tions of lesioned subpial cortex 
at indicated time points and 
in different animal groups. b 
Quantification of NogoA+ cells. 
At 3 days post-lesion induc-
tion, NogoA+ cell density is 
significantly decreased followed 
by significant repopulation 
(on day 21) after one and two 
demyelinating events. After 
four episodes of cortical lesion 
induction, a trend toward lower 
Ols counts (p = 0.052) is 
noted in comparison to naive 
controls. However, 35 days after 
the fourth lesion induction the 
density increases again to con-
trol levels. Data are expressed 
as mean + SeM. For statistical 
evaluation, one-way ANOVA 
followed by post hoc lSD 
test is performed (*p < 0.05, 
**p < 0.01). Scale bar 50 μm, 
length of enlarged image 14 μm
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axons was 40.5 ± 6.4 %. At the demyelination time point 
(day 3 after the last injection) the proportion of myelinated 
axons was markedly decreased (1st injection 1.3 ± 0.6 %, 
2nd injection 2.7 ± 1.1 %, 4th injection 0.5 ± 0.3 %) in 
rMOg-immunized rats. Three weeks after the last lesion 
induction, rMOg-immunized rats displayed a significantly 
higher proportion of myelinated axons than at the previ-
ous demyelination time point (p < 0.01 for 1st, 2nd and 4th 
injection). Furthermore, a similar fraction of myelinated 
axons was detected at the remyelination time point after one 
(16.2 ± 3.0 %), two (22.0 ± 3.8 %) and four (16.6 ± 3.0 %) 
stereotactic injections (Fig. 10c). Taken together, these data 
suggest that the rat cerebral cortex shows a high degree of 
endogenous oligodendroglial regeneration and remyelination 
capacity which does not seem to diminish even after four 
cycles of de- and remyelination in the targeted eAe model.
Discussion
Cortical demyelinated lesions in chronic MS patients 
were recently shown to be widespread and even to exceed 
Fig. 8  No reduction of Olig2+ oligodendrocyte precursor popula-
tion after repeated demyelination in rats. a representative photo-
graphs of Olig2 and PlP double-immunostained sections within the 
cytokine-injected subpial cortex. Merged overview photographs show 
Olig2+ precursors (red), PlP+ myelin (green) and DAPI+ nuclei 
(blue). Arrows point toward Olig2+ OPCs and white squares indi-
cate the area from which the insets are taken (upper image Olig2, 
middle: DAPI, lower merged image). b No significant reduction 
of Olig2+ cells is noted at any time point investigated compared to 
untreated controls. Furthermore, densities of Olig2+ cells are signif-
icantly higher on day 21 after the first injection and on day 3 after 
the fourth injection in rMOg-immunized mice. Data are expressed as 
mean + SeM. For statistical evaluation, one-way ANOVA followed 
by post hoc lSD test is performed (**p < 0.01). Scale bar 25 μm
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WM lesions with regard to lesion volume [19, 30]. Here, 
we investigated whether the densities of Ols and OPCs 
were altered in cortical lesions of early and late-stage MS. 
Furthermore, we examined the efficacy of OPC and Ol 
recruitment in cortical demyelinated lesions in a rat model 
of MS. Our data indicate that NogoA+ Ols as well as 
Olig2+ OPCs are substantially reduced in chronic, but not 
early cortical MS lesions. In our animal model, NogoA+ 
cell density was only transiently reduced in the affected 
cerebral cortex, but rapidly recovered to control levels even 
after four demyelinating episodes.
remyelination is considered to be an important mecha-
nism for long-term axonal protection and is thus of enor-
mous therapeutic interest. Accordingly, numerous studies 
have investigated the factors promoting remyelination in 
WM MS lesions [15]. Interestingly, the vast majority of 
early WM lesions harbor abundant NogoA+ and Olig2+ 
oligodendroglia and even contain newly formed myelin 
sheaths that enwrap previously demyelinated axons [33]. 
Although there is evidence for a variable degree of remy-
elination in around 40 % of chronic WM lesions,  complete 
remyelination is rare [21]. Furthermore, chronic late-stage 
WM lesions contain hardly any mature Ols and also 
only few OPCs. Cortical lesions show evidence for more 
extensive remyelination at the lesion border compared to 
chronic WM lesions [2, 12]. Nevertheless, persistent cor-
tical demyelination is an important feature of progressive 
MS, indicating that cortical remyelination fails at a certain 
Fig. 9  Transient increase of 
activated macrophages and 
microglia shortly after single 
and repeated cytokine injec-
tion in rats. a representative 
photographs show eD1-
immunostained sections within 
the cytokine-injected cortex on 
days 3 and 21 after last lesion 
induction of the indicated 
experimental groups. b Quan-
tification of eD1+ activated 
macrophages and microglia 
within cortical layer III. On day 
3 after lesioning, the density 
of eD1+ macrophages and 
microglia is significantly higher 
in rMOg- than IFA-immu-
nized animals after single or 
repeated, respectively, cytokine 
injection(s). Data are expressed 
as mean + SeM. For statistical 
evaluation one-way ANOVA 
followed by post hoc lSD 
test is performed (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
Scale bar 100 μm
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disease stage. It remains unclear which factors contribute 
to Ol demise and the failure of oligodendroglial differen-
tiation in chronic cortical MS lesions. Our findings of rela-
tively preserved axonal densities within chronic SCD argue 
against marked axonal loss as the decisive factor for corti-
cal remyelination failure. even though we cannot rule out 
the possibility that subtle axonal changes and degeneration 
may still occur in MS gM, such alterations are unlikely to 
result in OPC loss and the complete lack of remyelination 
observed in chronic SCD. It seems likely that other factors 
such as loss of local signals required for OPC survival and 
migration [39, 49, 51] contribute to remyelination failure. 
Furthermore, microglial, astrocytic and neuronal changes 
might contribute to reduced myelin regeneration in MS 
cortex.
One hypothesis investigated in the present study was 
that multiple demyelinating events may lead to failure of 
remyelination. This is mainly supported by experimen-
tal models of the disease [32]. repeated or sustained epi-
sodes of demyelination might finally exhaust the ability 
of OPCs to divide and differentiate into myelinating Ols. 
Alternatively, OPCs might be depleted from repeatedly 
Fig. 10  Unaltered remyelination after repeated cortical demyelina-
tion in rats. a representative photographs show MBP-immunostained 
sections within cytokine-injected cortex on days 3 and 21 after last 
lesion induction in rMOg-immunized animals and controls. b Quan-
tification of the demyelinated cortical area in rMOg- or IFA-immu-
nized animals following intracerebral cytokine injection. Animals 
immunized with rMOg show a similar size of cortical demyelina-
tion on day 3 after single or repeated lesion induction. likewise, 
the area of cortical demyelination is consistently decreased in these 
experimental groups on day 21 after single or repeated lesioning. In 
contrast, IFA-immunized controls (“IFA”) show no signs of demy-
elination. c Quantification of the myelinated axon fraction reveals a 
significant reduction of the myelinated axon fraction in demyelinated 
(day 3) animals compared to remyelinated (day 21) animals and con-
trols. The fraction of myelinated axons remains stable at the remy-
elination time point (day 21) after single versus repeated injection, 
but is still significantly lower than in controls. Data are expressed as 
mean + SeM. For statistical evaluation, one-way ANOVA followed 
by post hoc lSD test is performed (**p < 0.01, ***p < 0.001). Scale 
bar 100 μm
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demyelinated lesions and be unable to repopulate lesions 
from the periphery. In addition, multiple demyelinating 
episodes might furthermore change the tissue microenvi-
ronment and the susceptibility of axons to myelination.
In the present study we investigated if multiple cortical 
demyelinating events lead to the reduction of mature Ols 
and OPCs, thus limiting the extent of cortical remyelina-
tion. We employed a targeted eAe model based on subclin-
ical immunization with rMOg [38]. This model reproduces 
SCD found in MS patients and allows for precise lesion 
localization and timing. Our data indicate that repeated 
induction of cortical demyelination does not substantially 
affect the recruitment of OPCs, the generation of mature 
Ols or remyelination in rats. It should be noted, however, 
that a temporary reduction in mature Ols was observed 
after four cytokine injections, but Ol density recovered at 
later time points, indicating a slight delay in recruitment.
Our findings are in line with previous experimental work 
that relied on non-immunological mechanisms of demy-
elination. efficient remyelination was observed after three 
repeated injections of ethidium bromide into the cerebellar 
peduncle [40]. Similarly, unaltered remyelination capac-
ity was also observed in mice after two episodes of toxic 
cuprizone-induced demyelination [25]. These results in 
rodent models of CNS demyelination with good preserva-
tion of axons, driven by inflammation or by gliotoxic sub-
stances, highlight that endogenous remyelination capacity 
is not substantially impaired even after repeated episodes of 
demyelination.
In contrast to these experimental findings, patients with 
long-standing MS showed oligodendroglial depletion in 
chronic SCD as evidenced by reduced NogoA+ Ols and 
Olig2+ OPCs. The reduction of OPCs in chronic SCD sug-
gests that failure of cortical remyelination cannot simply 
be attributed to differentiation failure of OPCs, as it was 
suggested for WM MS lesions [11, 29, 42]. Furthermore, 
the strong reduction in Ols and OPCs observed in long-
standing human cortical MS lesions cannot be mimicked by 
recurrent demyelinating events in our experimental model. 
One might speculate that four courses of demyelination 
are not sufficient to exhaust the remyelinating capacity in 
the rat cortex. It is also conceivable that our model, which 
is based on anti-MOg antibody-mediated myelin destruc-
tion, may not fully mimic the pathogenesis of MS, where 
the target(s) of the immune reaction and the contribution 
of anti-myelin antibodies have not yet been determined. In 
addition, it is well known that remyelination in the rodent 
brain is a very robust phenomenon. As such, the loss of Ols 
and OPCs seen in chronic MS may represent a phenomenon 
that is specific to the disease process in humans. Our model 
thus is suited to study early lesion formation, but does not 
lead to the late-stage oligodendroglial deficiency and inabil-
ity to remyelinate as found in chronic MS lesions.
In early MS biopsies, NogoA+ mature Ols did not show 
any reduction in demyelinated cortical lesions, whereas a 
transient decrease was observed in the animal setting. How-
ever, it is important to note that the lesion stage of SCD is 
likely to differ between early human biopsy cases and rats 
with induced SCD. The animal model allows immediate 
investigations within 3 days after lesion induction, whereas 
this is not possible in patients who had already undergone 
a set of diagnostic investigations prior to biopsy. given 
these temporal differences, it may not be surprising that 
proliferating OPCs were only observed in rat, but not in 
human early SCD. Whether mature Ols observed in early 
MS lesions represent preserved or already repopulated Ols 
cannot be distinguished based on these single time point 
biopsies. Interestingly, we noted a trend toward higher OPC 
numbers in cortical layer I/II in MS biopsies which might 
indicate previous OPC proliferation.
One important factor associated with altered remyelina-
tion capacity and disease progression is aging [14]. In the 
current study we used up to 4- to 5-month-old rats with a 
follow-up period of up to 4 months. In contrast, human MS 
autopsy cases in this study had an average age of 54 years 
and showed a progressive disease course for at least 
10 years. Therefore, experiments in older animals might be 
required to test whether repeated induction of SCD would 
finally result in impaired cortical remyelination. Previous 
experimental studies showed reduced recruitment of OPCs 
into the lesion area and impaired oligodendroglial differ-
entiation in older animals [46, 47]. Furthermore, increased 
axonal vulnerability and decreased remyelination efficiency 
were recently reported in aged rats after targeted demy-
elination in the spinal WM [22]. Similarly, remyelination 
is less efficient in aged animals after lysolecithin [20] or 
cuprizone [45] induced demyelination. Mechanisms con-
tributing to such age-related effects may involve intrinsic 
determinants such as age-dependent epigenetic control of 
gene expression of OPCs [45] and extrinsic factors acting 
on OPCs in the lesion microenvironment [23, 52].
A recent study investigated the presence of Ng2+ poly-
dendrocytes in cortical demyelinated MS lesions and found 
similar densities in cortical demyelinated lesions, normal-
appearing and control cortex [12]. genetic fate mapping 
indicates that Ng2+ polydendrocytes can generate both 
Ols and astrocytes in gM [53]. Interestingly, constitutive 
deletion of Olig2 in Ng2+ cells leads to their conversion 
into astrocytes in the neocortex and corpus callosum [54]. 
These findings suggest that Olig2 is crucial for the differen-
tiation of Ng2+ polydendrocytes into Ols in the cerebral 
cortex. Thus, Ng2+ polydendrocytes lacking Olig2 expres-
sion in chronic SCD may have lost their capacity to differ-
entiate into myelin-forming Ols.
The precise pathogenetic mechanisms leading to SCD 
are still not known. However, chronic T- and B-lymphocytic 
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inflammation in the meninges was associated with shorter 
time to progression and more severe clinical disease in 
secondary progressive MS [36]. Meningeal inflammation 
and cortical demyelination were also recently identified 
as important features of primary progressive MS, which 
strongly suggests that inflammation and “neurodegenera-
tion” are closely linked phenomena in MS [13]. recent 
experimental findings indicate that the subarachnoid injec-
tion of proinflammatory cytokines is sufficient to induce 
cortical demyelination in MOg-immunized animals [16]. 
Consequently, chronically elevated cytokine levels may 
impede the proliferation, differentiation and survival of 
cortical Ols, and finally lead to persistent demyelination.
In conclusion, we show that oligodendroglial cells 
are present in early cortical MS lesions, but substantially 
decreased in chronic SCD. The latter could not be modeled 
in our experimental studies in which recruitment of Ols 
and remyelination were not impaired even after repeated 
cortical demyelination. This suggests that failure of corti-
cal remyelination in chronic MS may not simply result 
from repeated episodes of cortical demyelination affecting 
mature Ols, but may also require other factors damaging 
OPCs at an early differentiation stage. Further studies are 
needed to unravel the factors involved and mechanisms 
responsible for the cortical remyelination failure observed 
in progressive MS.
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